8-K: Cognition Therapeutics Unveils Strong Phase 2 Data for Zervimesine Across Neurodegenerative Diseases, Eyes Registrational Studies

Cognition Therapeutics, Inc. (CGTX) has reported compelling Phase 2 clinical trial results for its lead candidate, zervimesine (CT1812), demonstrating consistent efficacy signals in Alzheimer's disease, Dementia with Lewy Bodies (DLB), and dry Age-related Macular Degeneration (AMD), supporting plans for advancement to registrational studies.

Summary

• Zervimesine (CT1812), an oral, once-daily, BBB-penetrant small molecule oligomer antagonist, has shown consistent efficacy signals across three neurodegenerative indications.
• In the Phase 2 MAGNIFY study for geographic atrophy (GA) secondary to dry AMD, zervimesine treatment resulted in a 29% mean reduction in the rate of GA lesion growth compared to placebo (p=0.0538), with the effect increasing to 28.19% at 18 months (p=0.0074).
• The MAGNIFY study was voluntarily discontinued to prioritize resources on Alzheimer's and DLB programs, not due to safety concerns.
• The Phase 2 SHIMMER study in mild-to-moderate Dementia with Lewy Bodies (DLB) showed strong clinical signals across behavioral (86% slowing in NPI total, 114% in NPI distress), cognitive (85-91% slowing), functional (52% preservation in ADL), and movement (62% preservation in UPDRS) measures.
• The Phase 2 SHINE study in mild-to-moderate Alzheimer's disease demonstrated a 38% slowing on ADAS-Cog 11 overall, with a profound 95% slowing in cognitive decline observed in participants with below-median plasma p-tau217 levels.
• Zervimesine has a generally well-tolerated safety profile across over 450 treated individuals, with no amyloid-related imaging abnormalities (ARIA) observed, and a modest side effect profile.
• The company holds robust intellectual property covering zervimesine through 2040 with patent term extension (PTE).
• As of March 31, 2025, Cognition Therapeutics reported cash and cash equivalents of $16.4 million, with approximately $47 million in remaining grant funding from a total of ~$171 million for zervimesine studies.

Sentiment

Score: 8

Explanation: The document presents highly positive clinical trial results for zervimesine across multiple neurodegenerative indications, particularly strong signals in DLB and a promising subgroup in Alzheimer's. The oral dosing and favorable safety profile are significant advantages. While one study was discontinued, it was for strategic reasons, not safety. The remaining grant funding also provides a solid financial runway.

Positives

• Zervimesine demonstrated consistent efficacy signals in three distinct neurodegenerative diseases: Alzheimer's, DLB, and dry AMD.
• The drug is effective in both mild and moderate Alzheimer's disease, a broad patient population.
• In dry AMD, zervimesine treatment reduced GA lesion growth by 29% on average, with the effect strengthening over time to 28.19% at 18 months.
• Zervimesine showed strong responses across behavioral, functional, cognitive, and movement measures in the Phase 2 SHIMMER study for DLB, positioning it as a potential first-to-market therapy.
• A significant cognitive impact (95% slowing) was observed in Alzheimer's patients with lower plasma p-tau217 levels in the SHINE study, identifying a strong responder group.
• The safety profile is generally well-tolerated across over 450 treated individuals, with no ARIA, which is a common side effect of other Alzheimer's therapies.
• Oral once-daily administration of zervimesine offers a reduced burden compared to intravenous Alzheimer's therapies requiring imaging surveillance or intravitreal injections for dry AMD.
• The company possesses robust intellectual property for zervimesine, extending through 2040 with patent term extension.
• Significant remaining grant funding of approximately $47 million provides financial support for ongoing and future zervimesine studies.

Negatives

• The MAGNIFY study for dry AMD was voluntarily discontinued, indicating a strategic shift away from this indication despite positive results.
• While generally well-tolerated, liver enzyme elevations (LFTs >= 3x ULN) were observed in 8.2% of zervimesine-treated patients in MAGNIFY and in the 300mg dose group in SHINE, requiring monitoring.
• The overall p-value for ADAS-Cog 11 in the SHINE study (0.310) was not statistically significant, with the strong cognitive impact primarily observed in a prespecified subgroup analysis (below median plasma p-tau217).

Risks

• Uncertainties inherent in preliminary data, preclinical studies, and earlier-stage clinical trials being predictive of results in later-stage trials.
• The timing, scope, and likelihood of regulatory filings and approvals for product candidates, including zervimesine, are uncertain.
• Competition from other pharmaceutical companies developing treatments for neurodegenerative diseases.
• Ability to secure new and retain existing grant funding, which is a significant source of financing for the company's studies.
• Challenges in growing and managing growth, maintaining relationships with suppliers, and retaining management and key employees.
• Changes in applicable laws or regulations could adversely affect the business.
• The company may be adversely affected by other economic, business, or competitive factors, including ongoing economic uncertainty.
• Estimates of expenses and profitability may not be accurate.
• The evolution of the markets in which the company competes could impact its business.
• Ability to implement strategic initiatives and continue to innovate existing products.
• Ability to defend intellectual property rights against infringement.
• Impacts of global political changes and global economic conditions on the business, supply chain, and labor force.
• Ability to maintain the listing of common stock on the Nasdaq Global Market.

Future Outlook

Cognition Therapeutics plans to request an End-of-Phase 2 meeting with the FDA to establish a protocol for a Phase 3 study in Alzheimer's disease, specifically targeting a population defined by plasma p-tau217 levels. The company is also continuing its 540-person START study in amyloid-positive early Alzheimer's disease, which is the first study to allow lecanemab as background therapy in combination with zervimesine.

Management Comments

• Lisa Ricciardi, President and Chief Executive Officer, highlighted the compelling data from zervimesine as a first-in-class oligomer antagonist, supporting a registrational plan.
• Management emphasized the consistent efficacy signals observed in Alzheimer's, DLB, and dry AMD, along with the generally well-tolerated safety profile and oral once-daily administration.
• The company views zervimesine as having the potential to be first-to-market for dementia with Lewy bodies due to strong responses across multiple symptom measures in the SHIMMER study.

Industry Context

Cognition Therapeutics is developing zervimesine as a novel, oral small molecule for neurodegenerative diseases, a field dominated by large molecule (antibody) therapies, particularly in Alzheimer's. Its distinct mechanism of action targeting pathogenic oligomers, rather than plaque clearance, offers a differentiated approach. The oral, once-daily dosing could provide a significant convenience advantage over existing intravenous or intravitreal treatments, potentially improving patient adherence and quality of life. The strong signals in DLB position zervimesine to potentially address a significant unmet medical need as a first-in-class therapy for this indication.

Comparison to Industry Standards

• In geographic atrophy (GA), zervimesine's 29% mean reduction in GA lesion growth rate over 18 months (with 28.19% at 18 months) compares favorably to existing intravitreal therapies like IZERVAY (avacincaptad pegol), which showed 35% reduction at 18 months in Gather1 and 14% at 24 months in Gather2, and SYFOVRE (pegcetacoplan), which showed 13% in Derby and 22% in Oaks at 18 months. Zervimesine's oral administration offers a significant advantage over these intravitreal injections.
• For Alzheimer's disease, zervimesine's observed 95% slowing of cognitive decline in the below-median plasma p-tau217 subgroup is a strong signal, especially when compared to the 36% slowing in the low tau tercile for donanemab (TRAILBLAZER 2) on iADRS, suggesting a potentially competitive efficacy profile for a specific patient population, with the added benefit of oral dosing and no ARIA risk.
• In Dementia with Lewy Bodies (DLB), zervimesine's strong and consistent signals across behavioral, cognitive, functional, and motor domains position it as a potential first-to-market therapy, as there are currently no FDA-approved disease-modifying treatments specifically for DLB, unlike Alzheimer's where several amyloid-targeting therapies exist.

Stakeholder Impact

• Shareholders: Positive clinical trial results and plans for registrational studies could lead to increased investor confidence and potential share price appreciation.
• Patients: Zervimesine offers a potential new, orally administered treatment option for debilitating neurodegenerative diseases like Alzheimer's, DLB, and dry AMD, potentially improving quality of life and slowing disease progression.
• Employees: Continued positive clinical development supports job security and potential growth opportunities within the company.
• Regulatory Authorities: The company's engagement with the FDA for Phase 3 planning indicates progress towards potential market approval, which could benefit public health.

Next Steps

• Request an End-of-Phase 2 meeting with the FDA to establish the protocol for a Phase 3 study in Alzheimer's disease, focusing on a population defined by plasma p-tau217 levels.
• Continue recruitment and conduct of the ongoing 540-person Phase 2 START study in amyloid-positive early Alzheimer's disease, which allows lecanemab as background therapy.

Key Dates

Recommendation

Keywords

Zervimesine, CT1812, Alzheimer's Disease, Dementia with Lewy Bodies, Dry Age-related Macular Degeneration, Geographic Atrophy, Neurodegenerative Diseases, Oligomer Antagonist, TMEM97, Sigma-2 Receptor, Clinical Trials, Phase 2, Biotechnology, Pharmaceuticals, Cognition Therapeutics, CGTX, SEC Filing, 8-K, Investor Presentation